Stockreport

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS) - - Secured development and commercializa [Read more]